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Abstract 
Objective To ascertain the clinical and genetic factors contributing to carbamazepine and 
oxcarbazepine induced hyponatremia (COIH), and to carbamazepine (CBZ) metabolism, in a 
retrospectively collected, cross-sectional cohort of people with epilepsy. 
Methods We collected data on serum sodium levels and anti-epileptic drug levels in people 
with epilepsy attending a tertiary epilepsy centre while on treatment with CBZ or OXC. We 
defined hyponatremia as Na+ ≤134 mEq/L. We estimated the CBZ metabolic ratio defined as 
the log transformation of the ratio of metabolite CBZ-diol to unchanged drug precursor 
substrate as measured in serum. 
Results Clinical and genetic data relating to carbamazepine and oxcarbazepine trials were 
collected in 1,141 subjects. We did not observe any genome-wide significant associations 
with sodium level in a linear trend or hyponatraemia as a dichotomous trait. Age, sex, number 
of co-medications, phenytoin use, phenobarbital use and sodium valproate use were 
significant predictors of CBZ metabolic ratio. No genome-wide significant associations with 
CBZ metabolic ratio were found. 
Significance While we did not detect a genetic predictor of hyponatraemia or CBZ 
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metabolism in our cohort, our findings suggest the determinants of CBZ metabolism are 
multifactorial.  
 
Key Points 
• No large, clinically-relevant genetic predictors of carbamazepine- or oxcarbazepine-
induced hyponatraemia. 
• Age and concurrent phenytoin, phenobarbital or sodium valproate significantly associated 
with carbamazepine metabolic ratio. 
• No large, clinically-relevant genetic predictors of carbamazepine metabolic ratio. 
 
Introduction 
Carbamazepine (CBZ) and its keto-analogue, oxcarbazepine (OXC), are routinely used as 
antiepileptic drugs and also used in the treatment of chronic pain conditions and in bipolar 
disorder. While effective, their use is limited by adverse drug reactions (ADRs), including 
hyponatremia and hypersensitivity. Carbamazepine- and oxcarbazepine-induced 
hyponatremia (COIH) is reported in up to half of drug exposures. This is often assumed to be 
asymptomatic but it can lead to difficulties ranging from unsteadiness and mild confusion to 
seizures and coma. Careful dose titration and monitoring of sodium levels are recommended 
for reducing the risk of COIH while individual differences in drug metabolism can make 
titration difficult.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
HLA-B*1502 is strongly associated with CBZ-induced Stevens-Johnson syndrome (SJS) in 
people of Han-Chinese ethnicity, increasing the risk about 100 fold1. In individuals of 
European descent, HLA-A*3101 is a clinically relevant predictor for the full spectrum of 
CBZ-induced hypersensitivity reactions2,3. To date, no genetic risk factors have been 
associated with COIH. Thiazide-induced hyponatremia is associated with two polymorphisms 
in the KCNJ1 gene, encoding the renal outer medullary potassium channel (ROMK) which 
plays an important role in sodium reabsorption along the thick ascending limb of the Loop of 
Henle4. CBZ and OXC seem to influence water reabsorption, independent of salt retention, 
via stimulation of the vasopressin 2 receptor/aquaporin (AVPR2) pathway5. Mutations in the 
AVPR2 gene, a regulator in water reabsorption, can cause a nephrogenic syndrome of 
inappropriate antidiuresis (NSIAD) with physiological similarities to the inappropriate 
antidiuresis induced by CBZ and OXC6. Studies of AVPR2 copy number variation, however, 
did not explain variation in sodium levels in non-Hispanic Caucasian populations7.  
We attempted to determine the clinical and genetic factors contributing to COIH and drug 
metabolism in a retrospectively collected, cross-sectional cohort of people with epilepsy of 
European descent treated with CBZ and OXC previously described8.  
 
Methods 
Study design and phenotypes: 
We followed a retrospective cohort study design. The majority of subjects were recruited at a 
Dutch tertiary epilepsy referral centre (SEIN) while the remainder were recruited around 
European tertiary referral clinics associated with the EpiPGX Consortium.  Clinical 
information from medical records, with an emphasis on AED history, was recorded in an 
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electronic database designed for retrospective pharmacogenomics studies9. The database was 
used to identify all individuals who were prescribed CBZ or OXC and who had a recorded 
serum sodium level during therapy. Most individuals had several measurements and the 
lowest sodium level recorded was selected for analysis. Our primary analyses were structured 
to test genetic variants for association with this lowest recorded sodium level per subject 
(mEql/L). Secondary analyses tested for genetic association with i) COIH (combined and per 
causal drug) and ii) CBZ metabolic ratio. In a subset of CBZ users for which we had 
concurrently measured CBZ-10,11-diol (CBZ-diol) levels, we calculated the metabolic ratio 
defined as the log transformation of the ratio of metabolite CBZ-diol to unchanged drug 
precursor substrate as measured in serum. COIH cases were defined as having a blood sodium 
level ≤134 mmol attributed to carbamazepine or oxcarbazepine as determined by their 
clinician. COIH controls trialled carbamazepine or oxcarbazepine for at least three months 
with a sodium level ≥135 mmol. Epilepsy-specific cohort demographics are presented in 
Table 1. 
 
Sampling and Genotype analysis: 
Serum drug and metabolite concentrations were measured during the course of routine 
monitoring in the morning prior to drug intake. For each sodium level measurement, we 
recorded subject age, serum level of CBZ or OXC and concomitant use of other drugs. 
Genotyping of all subjects was performed at deCODE Genetics on Illumina OmniExpress-12 
v1.1 and OmniExpress-24 v1.1 single nucleotide polymorphism (SNP) arrays. Genotyping 
quality control was performed as described previously10. Principal components analysis 
(PCA) was performed with European-ancestral samples from the HapMap Project to assess 
cohort substructure and identify population outliers (Supplementary Figure 1). Eigenvectors 
were computed in GCTA for each subject for inclusion as covariates in genetic association 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
testing11. Subjects were identified as outliers and removed if greater than three standard 
deviations from the first eight principal components. We used FUMA to generate Manhattan 
and quantile-quantile (Q-Q) plots12. 
Study power: 
We estimated from our recruited sample size that our study had 80% power to detect a genetic 
predictor of relative risk (approximated to odds ratio) ≥ 3 with an allele frequency ≥ 2% and 
an alpha level of 1.0x10-8. 
Statistical analyses: 
Clinical cofactors influencing sodium levels and COIH in this cohort were previously 
reported and used as covariates in our models8. Association analyses were conducted using 
additive linear or logistic regression models in PLINK, including clinical covariates where 
appropriate and eight principal components from PCA. Dosage, number of co-medications 
and AED levels were excluded from genetic analyses due to missing information in the 
EpiPGX subcohort. We also analysed the significance of clinical variables influencing CBZ 
metabolic ratio using a stepwise linear regression model in SPSS. As before, significant 
clinical cofactors from the linear regression model were included as covariates along with 
eight principal components from PCA. For each association test, SNPs with < 90% call rate 
were excluded. The threshold for genome-wide statistical significance was set at 1.0x10-8, 
reflecting an empirical Bonferroni correction, for five tests, of the standard 5x10-8 genome-
wide significance threshold.  
Ethical considerations: 
All study participants provided written, informed consent for genetic analysis. Study protocols 
were approved by the research ethics committees listed in Supplementary Table 1. 
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Results 
We collected clinical and genetic data relating to carbamazepine (n=1,031 subjects) and 
oxcarbazepine (n=297 subjects) trials. A subset (n=79 subjects) were trialled on 
carbamazepine and oxcarbazepine. Of the total 1,252 subjects, 1,047 were recruited at SEIN 
while 201 were recruited through EpiPGX partner sites. Data on drug levels and compliance 
were available for 98% of the SEIN cohort, but not for the EpiPGX partner sites. In 5% of our 
SEIN cohort the drug levels or dosage was below therapeutic values (for CBZ< 4 mmol/l or < 
400 mg/day, for OXC <10 mmol/l or <900 mg/day). We report 448 cases with COIH, 804 
controls with normal serum sodium measurement. Within our cases there were a subset of 61 
subjects with extreme hyponatraemia. The incidence of OXC-induced hyponatraemia (57%) 
was almost two-fold higher than that of CBZ (32%). Characteristics of our cohort are 
described in Table 1. A total of 25 subjects were removed after genotyping quality control. 
To test whether common genetic variants predict sodium levels, we performed a genome-wide 
linear regression adjusted for age, clobazam use, sex, plus eight principal components.  We 
did not observe any genome-wide significant associations with sodium level (Figure 1).  
To test whether common genetic variants predict COIH, defined as a serum sodium level 
<135mEq/L, we performed a case-control genome-wide logistic regression adjusted for sex, 
age < 40, plus eight principal components. We did not observe any genome-wide significant 
associations when we considered COIH as a dichotomous trait (Figure 2). There was a 
suggestive association signal (p<1x10-6) from chromosome 5, in an intergenic region 
approximately 500Mb downstream of the gene ANKRD55, evident in the quantitative and 
dichotomous analyses of sodium. Further, we did not detect evidence for a genetic signal in a 
subset of 61 severe COIH cases, defined as serum sodium ≤125mEq/L, when compared to 
controls. Neither did we did observe any significant associations when we differentiated 
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hyponatraemia by causal drug (see Supplementary Figures 2-4). Given prior reports of an 
association with thiazide-induced hyponatraemia, we looked closely within the genes KCNJ1 
and AVPR2, yet we did not observe any signals of association in our data.  
Next, we explored whether clinical cofactors or genetic variants could predict the ratio of 
active drug to metabolite in our CBZ-exposed subjects. We modelled the contribution of 
clinical cofactors to CBZ metabolic ratio and found that age, sex, number of co-medications, 
phenytoin use, phenobarbital use and sodium valproate use were significantly predictive of 
outcome (adjusted r2=0.236, Model 5 in Table 2).  
To test whether common genetic variants predict CBZ metabolic ratio, we then performed a 
genome-wide linear regression adjusted for the covariates in Model 5, plus eight principal 
components. We did not observe any genome-wide significant associations with CBZ 
metabolic ratio. The top ten most significant GWAS markers for each analysis are listed in 
Supplementary Tables 1-5. Polymorphisms in CYP3A4 and EPHX1 have been shown to 
associate with inter-individual variability of CBZ metabolism14,15. We did not observe even 
nominally significant associations between SNPs in CYP3A4 and CBZ metabolic ratio. It had 
been reported that homozygous carriers of the EPHX1 c.416A>G SNP (rs2234922) seemingly 
show a reduced CBZ metabolism as measured by a significantly decreased metabolic ratio16. 
We did not replicate this finding (rs2234922; p= 0.303) but we observed a nominally 
significant association between an intronic EPHX1 SNP (c.365-2139T>C) and CBZ 
metabolic ratio (rs4653689; p=1.1x10-4).  
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Discussion 
While we did not detect a genetic predictor of hyponatraemia in our cohort, we have 
demonstrated that the determinants of CBZ metabolism are multifactorial. Modelling the 
contribution of clinical variables showed there were strong non-genetic predictors of CBZ 
metabolism. Subject age, total number of co-medications and the concurrent use of either 
phenytoin, phenobarbital or sodium valproate were significantly associated with a higher 
CBZ-diol to CBZ ratio. Much of this can be explained by the induction of the cytochrome 
P450 enzyme CYP3A4. CBZ is metabolised in the liver by CYP3A4 to carbamazepine-10,11-
epoxide which is further metabolised by microsomal epoxide hydrolase (mEH) to 
carbamazepine-10,11-diol.17 Phenytoin and phenobarbital induce CYP3A4 and thus can 
lower plasma CBZ levels but leave the metabolite levels unaltered, which results in the 
observed higher metabolic ratio18,19. Sodium valproate inhibits epoxide hydrolase, 
potentiating higher levels of the active metabolite CBZ-10,11-epoxide which is associated 
with toxicity and adverse events,20 but this was not directly measured in this study. Valproate 
has been shown to increase dose ratios between CBZ and its metabolites, for both the diol and 
epoxide forms.21 Age has previously been found to contribute to pharmacokinetic variability 
in individuals using CBZ with increasing clearance until age 33 and a gradual decrease 
towards older age22.  
A limitation of the study is that AED dosage was not reliably recorded in our cohort and we 
had to make an assumption that the measurement of CBZ metabolic ratio was independent of 
the individual subject’s dosage. In the subset of subjects for whom serum CBZ-diol and CBZ 
dosage information was available (n=40) we did not detect a significant effect of CBZ dose 
on the metabolic ratio (p=0.41).  
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CBZ and OXC are widely prescribed but their use coincides with a high prevalence of COIH. 
Within our cohort OXC-induced hyponatraemia has a much higher prevalence than that of 
CBZ, which is consistent with previous estimates.23,24 From clinical experience, susceptibility 
to COIH is individually variable. Experimental studies and a recent clinical report suggest 
COIH is caused by a direct effect of CBZ/OXC on the kidney by stimulating the vasopressin 
receptor25,26. Mutations in the V2R/AQP2 pathway regulating water reabsorption can cause 
disorders clinically similar to the syndromes of inappropriate secretion of antidiuresis 
associated with CBZ/OXC use. Meanwhile thiazide-induced hyponatremia has been 
associated with polymorphisms in the gene KCNJ1 and a suggestive association with a variant 
in SLCO2A1, encoding a prostaglandin transporter; these signals did not show even nominal 
significance in our data4,27. We further looked for an effect from these markers within the 
subset of 53 subjects who experienced hyponatraemia on both CBZ and OXC independently, 
but there was no significant enrichment. 
Previously described clinical predictors of serum sodium levels only explain 11-14% of the 
variance in the SEIN cohort8. Therefore, it is hypothesized that genetic variation could in part 
explain the variation in susceptibility to COIH. Yet, after analysing sodium levels in a linear 
trend and hyponatraemia as a dichotomous trait, we did not find genetic predictors for COIH. 
A recent report of variants in NFAT5 and SLC4A10 with suggestive association with plasma 
osmolality further imply a genetic component to hyponatraemia but these variants showed no 
evidence for effect on serum sodium measurements in our study, albeit we were not as 
powered as the original discovery cohort28.  
In summary, our study rules out common genetic variants of clinically relevant effect size, 
however genetic susceptibility for COIH cannot be ruled out completely, as rare variants and 
combinations of genetic variants of smaller effect size (polygenic risk) may contribute to 
overall risk.  Further study, ideally in a prospective cohort with baseline sodium level and 
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CBZ-diol measurements, is warranted to investigate the genetic contribution to CBZ and 
OXC-induced hyponatremia.  
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Tables 
Description CBZ OXC Combined 
Subjects 1,031 297 1,252a 
% male 51.4% 48.1% 51.2% 
Mean age (± SD) 42.9 ± 15.1 38.1 ± 15.9 41.9 ± 15.6 
No. AED Co-medications (max)b 1.0 (5) 0.9 (4) 1.0 (5) 
Hyponatraemia (Na < 135mEq/L) 331 (32%) 170 (57%) 448c 
Mean case serum sodium (mEq/L) 129.5 ± 4.1 127.5 ± 4.2 129.0 ± 4.2 
Mean control serum sodium (mEq/L) 139.8 ± 2.5 139.4 ± 2.7 139.7 ± 2.5 
Mean serum AED level (mg/L) (± SD) b 8.7 ± 2.3 17.8 ± 8.2 - 
Metabolic ratio (± SD)d 0.35 ± 0.21 - - 
Table 1: CBZ and OXC cohort characteristics. a 79 subjects trialled both CBZ & OXC. b 
Calculated from SEIN subcohort (n=1074). c 53 subjects experienced hyponatraemia on both 
CBZ & OXC. d Metabolic ratio calculated on subset of subjects with serum CBZ-diol level 
readings (n=468). 
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Model Factors R R Square Adjusted R Square Std. Error 
1 PHT .363a .132 .130 .196 
2 PHT, NoCoMed .421b .177 .174 .191 
3 PHT, NoCoMed, Age .458c .210 .205 .188 
4 PHT, NoCoMed, Age, PHB .486d .236 .230 .185 
5 PHT, NoCoMed, Age, PHB, VPA .493e .243 .236 .184 
Table 2: Stepwise linear regression of carbamazepine metabolic ratio. PHT: phenytoin, 
NoCoMed: number of co-medications, PHB: phenobarbital, VPA: sodium valproate 
 
Figures 
 
Figure 1: Manhattan and Q-Q plots of sodium levels (λ = 1.00).  
Figure 2: Manhattan and Q-Q plots of COIH (λ = 1.00).  
Figure 3: Manhattan and Q-Q plots of carbamazepine metabolic ratio (λ = 0.98).  
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